A recent study from researchers in Canada and Japan describes a new possible target for the treatment of amyotrophic lateral sclerosis (ALS). The paper, titled “Ubiquilin-2 drives NF-κB activity and cytosolic TDP-43 aggregation in neuronal cells,” appeared on Oct. 31 in the journal Molecular Brain.
Because amyotrophic lateral sclerosis (ALS) is such a devastating disease, there is a need for novel and efficacious therapies and several studies hypothesize that growth hormone may be one of them. In a new review paper titled “The neuroprotective effects of human growth hormone as a potential treatment for amyotrophic lateral…
A consortium dedicated to finding a cure for amyotrophic lateral sclerosis (ALS), comprised of ALS ACT, The ALS Association, ALS Finding a Cure, and the Translational Research Advancing Therapy ALS (TREAT ALS™) Northeast ALS Consortium (NEALS), has just announced the official start of acceptance of proposals for Phase II clinical trials for potentially groundbreaking treatments for the disease.
An ALS Association-sponsored meeting, held at Cold Spring Harbor Laboratory in Huntington, New York, brought together expert researchers to discuss three main themes in current amyotrophic lateral sclerosis (ALS) research: antisense therapy, gene therapy and stem cell therapy. Recent ALS therapeutic approaches have not been very successful, with only one drug,…
Three recent studies published in the journals Nature and Nature Neuroscience identified a mutation in some forms of amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) that leads to neuronal death by disrupting the movement of molecules within the cellular nucleus. ALS and FTD are characterized by death…
Biopharmaceutical MediciNova, Inc. will be present at the 26th International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease) to host a session on its therapeutic strategies for the treatment of Amyotrophic Lateral Sclerosis (ALS). The company announced it will participate in the symposium to…
Two non-profit organizations, ALS Association and Prize4Life, have joined forces to launch a new challenge grant program called The ALS Assistive Technology Challenge. Inaugurated with an initial investment of close to $500,000, the new program intends to support research projects focused on new communication technology solutions for patients who suffer from…
The finding and validation of specific disease biomarkers are an unmet medical need for amyotrophic lateral sclerosis (ALS) early diagnosis, patient care and monitoring. Neurofilaments, proteins that provide cytoskeletal support to neurons, are front and center in this scientific quest. Several studies have investigated the role of cerebrospinal fluid (CSF) neurofilaments in…
University of Toronto (UT) researchers have uncovered the main genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), a discovery that will lead to the development of new efficacious treatments. The work entitled, “Isoform-specific antibodies reveal distinct subcellular localizations of C9orf72 in amyotrophic lateral…
